{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T19:10:12Z","timestamp":1674155412132},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.atherosclerosis.2012.01.016","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T23:04:35Z","timestamp":1326495875000},"page":"478-483","source":"Crossref","is-referenced-by-count":2,"title":["In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?"],"prefix":"10.1016","volume":"221","author":[{"given":"Mark T.","family":"Ledwidge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Kerins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Cefali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shona","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Gilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0010","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/ATVBAHA.108.171363","article-title":"Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice","volume":"28","author":"Van der Hoorn","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2008.04.044","article-title":"Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells","volume":"202","author":"Ganji","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in coronary drug project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0025","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A \u201chot\u201d topic in dyslipidemia management\u2014\u201chow to beat a flush\u201d: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0040","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1034\/j.1600-0773.2002.900608.x","article-title":"Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man","volume":"90","author":"Saareks","year":"2002","journal-title":"Pharmacology and Toxicology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0050","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0055","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CPP45078","article-title":"Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation","volume":"45","author":"Cefali","year":"2007","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0065","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/jm801094c","article-title":"Discovery of a \u201ctrue\u201d aspirin prodrug","volume":"25","author":"Moriarty","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0070","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1021\/jm900561s","article-title":"Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups","volume":"52","author":"Jones","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0075","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0021-9150(94)90093-0","article-title":"Plasma low density lipoprotein cholesterol concentration in cynomolgus monkeys: differing effects of age and body weight in animals consuming low and high cholesterol diets","volume":"111","author":"Colvin","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1750-3639.2009.00038.x","article-title":"Thyroid hormone \u03b2 receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys","volume":"156","author":"Ito","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0090","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","article-title":"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes","volume":"109","author":"Hundal","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0155","article-title":"Risk factors for discontinuation of statin medications: evidence from a large national pharmacy claims database","volume":"116","author":"Davidson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.atherosclerosis.2006.02.025","article-title":"Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany","volume":"190","author":"B\u00f6hler","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes","volume":"152","author":"Goldfine","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.2042-7158.2011.01380.x","article-title":"Mechanisms of aggregation inhibition by aspirin and nitrate\u2013aspirin prodrugs in human platelets","volume":"64","author":"Harmon","year":"2012","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0115","article-title":"Differential inhibition of tumour cell-induced platelet aggregation by nicotinate aspirin prodrug (ST0702) and aspirin","author":"Medina","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0120","series-title":"Physicians\u2019 desk reference","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0095","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, AIM-HIGH Investigators","volume":"365","author":"Boden","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0130","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1210\/jc.2009-2392","article-title":"Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus","volume":"95","author":"Ertugrul","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.atherosclerosis.2012.01.016_bib0145","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915012000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915012000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T03:26:54Z","timestamp":1543289214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915012000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0021915012000494"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.01.016","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}